Collplant Biotechnologies Ltd. · NASDAQ:CLGN
Collplant Biotechnologies — Investor Presentation (2026)
31 slides from Collplant Biotechnologies's investor presentation, 2026
Slide 1: CollPlant Corporate Presentation
CollPlant Corporate Presentation Nasdaq: CLGN 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements The statements made in this presentation speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change. Unless otherwise required by applicable securities laws, we do not intend, nor do we undertake any obl
Slide 3: About CollPlant
About CollPlant A regenerative medicine company developing innovative technologies and products for medical aesthetics, tissue regeneration, and organ manufacturing The Company's products and candidates are based on rhCollagen that is produced in genetically engineered tobacco plants Clinically vali
Slide 4: Collagen is an Essential Component of the Human Body
Collagen is an Essential Component of the Human Body 25% to 35% of the whole-body protein content The main structural protein in the extracellular matrix found in the body’s organs and various connective tissues* Ideal scaffolding molecule for regenerative medicine *(e.g. cartilage, bones, tendons,
Slide 5: Our Technology Platform Produces Human Collagen in Plants at Mass-Scale
Our Technology Platform Produces Human Collagen in Plants at Mass-Scale COL1⍺1 COL1⍺2 P4H⍺ P4Hß LH3 N- propeptide C- propeptide 5
Slide 6: Human Collagen Platform
Human Collagen Platform Clear advantages over tissue-extracted (animal-derived) collagen Plant-derived Animal Extracted = Cell binding domains Human-identical Xeno-free (plant- Tunable properties High consistency Biologically active (non- collagen derived) immunogenic, ECM- mimetic) 6
Slide 7: Our Product Pipeline
Our Product Pipeline Product Use Preclinical Clinical Commercial Status/Partner Regenerative Aesthetic Injectable tissue fillers Dermal/soft tissue fillers Photocurable filler Dermal/soft tissue fillers Regenerative medicine Breast reconstruction Breast implants and augmentation Soft Tissue Repair &
Slide 8: Dermal/Soft Tissue Fillers
Dermal/Soft Tissue Fillers 8
Slide 9: Dermal Fillers: Market Overview
Dermal Fillers: Market Overview 6% ~5.3M Hyaluronic Acid procedures in 2023 in the US1 7% 2% $6.3B, 10.3% CAGR 77% 2020 Procedure breakdown, 4% Global dermal filler market, 2023, CAGR 2023-20332 U.S (by material)4 4% $100-$250/unit Cost per syringe3 Polymethyl methacrylate microspheres Fat Polylacti
Slide 10: From Volume to Regenerative Structural Fillers
From Volume to Regenerative Structural Fillers Market CollPlant CollPlant Next Gen HA fillers HA–rhCollagen fillers Photocurable filler volume only Regenerative fillers regeneration + shape control Programmable Structural Regeneration A New Category in Aesthetics 10
Slide 11: HA–rhCollagen: A Regenerative Filler
HA–rhCollagen: A Regenerative Filler HA (volumization) Regenerative Filler Immediate volumization Supports tissue regeneration High biocompatibility rhCollagen (biology) 11
Slide 12: Regenerative HA-rhCollagen Filler Platform
Regenerative HA-rhCollagen Filler Platform • Hybrid HA + rhCollagen Technology Combines the immediate volumizing effect of hyaluronic acid with the regenerative bioactivity of recombinant human collagen for natural-looking aesthetic outcomes. • Designed for Natural Tissue Integration Designed to pro
Slide 13: HA-rhCollagen Photocurable Regenerative Dermal Filler
HA-rhCollagen Photocurable Regenerative Dermal Filler 13
Slide 14: Inject → Shape → Light → Fix
Inject → Shape → Light → Fix Injection Sculpting Photocuring in-situ rhCollagen-HA formulation Filler Features: Structural scaffold formation Precise contouring Tissue integration 14
Slide 15: Introducing the Photocurable rhCollagen Platform
Introducing the Photocurable rhCollagen Platform Light-activated in-situ Structural fixation High G’ scaffold for Contouring control Human-identical rhCollagen For biological integration
Slide 16: A Photocurable Dermal Filler would be an all-in-one innovation
A Photocurable Dermal Filler would be an all-in-one innovation: High Flexibility Flexibility compliance with facial expression Moldability precise contour definition Cohesivity High High Elasticity Cohesivity maintains the defined shape Elasticity Recovers original shape (aligned with facial express
Slide 17: KOL Testimonial: Dr. Jason Bloom
Full video at: https://www.youtube.com/watch?v=D114gdmrdek KOL Testimonial* Dr. Jason Bloom MD, FACS BLOOM FACIAL PLASTIC SURGERY • “The first injectable moldable implant” • “Provides cohesivity and structural support that far exceeds anything in the market” • “A customizable implant that can be imp
Slide 18: KOL Testimonial: Dr. Sachin Shridharani
Full video at: https://youtu.be/FvdcfO5sQTw KOL Testimonial Dr. Sachin M. Shridharani, MD, FACS Director - LUXURGERY (New York, NY) • “It changes the overall approach of long-lasting facial sculpting” • “Transforming an injectable filler into a solid-like gel” • “It forms an elastic, cohesive and in
Slide 19: GLP-1 Opportunity
GLP-1 Opportunity A new aesthetic challenge driven by metabolic weight loss • Rapid fat pad deflation • Loss of facial structural support • Unmet need beyond conventional fillers 19
Slide 20: Commercial Product Portfolio
Commercial Product Portfolio 20
Slide 21: rhCollagen BioInk Components
rhCollagen BioInk components ECM components Direct Ink Writing (DIW) (biological/ physical properties) s ie o g k Components l Polymers Inkjet o t i n g te c h n (physical properties) Ceramics CollInk-3D Projection p r in 20ml n (hard tissue) Stereolithography I Bio B io 3D Nanoparticles Tomographic
Slide 22: rhCollagen-based Bioink Platform for Biofabrication
rhCollagen-based Bioink Platform for Biofabrication Animal-free: excellent safety profile, non immunogenic Optimal rheology at room temperature Cytocompatible biofunctional Compatible with major printing technologies Mass production. consistency, robustness High homogeneity reproducibility 22
Slide 23: 3D Bioprinting Represents a Wide Range of Development Opportunities
3D Bioprinting Represents a Wide Range of Development Opportunities Develop in-house or with Develop in collaboration with leading collaborators life sciences companies Development cost Tissues Organs • Breast • Lungs • Heart valve • Kidney • Cornea • Liver Scaffolds • Skin • Heart • Spine fusion •
Slide 24: 3D-bioprinted Regenerative Breast Implants
3D-bioprinted Regenerative Breast Implants 24
Slide 25: Revolutionary Option: The Ability to Regenerate Breast Tissue
Revolutionary Option: The Ability to Regenerate FDA Alert: Patients with breast Breast Tissue implants have an increased risk of developing breast No regenerative breast implant exists implant Associated- Anaplastic Large Cell Safety issues exist with silicone breast Lymphoma implants (June 2023)* *
Slide 26: Breast Implant Market Overview
Breast Implant Market Overview $3.0B Market Reconstruction worldwide (2024)1 $ 5-10K Cost Procedure (US segmentation) per full procedure in US2 60% Breast 21% Augmentation ~2,200,000 Breast Lift Breast implant procedures WW (2022) 3 1. www.imarcgroup.com/breast-implant-market 2. www.webmd.com/beauty
Slide 27: CollPlant's 3D Bioprinted Breast Implants
CollPlant’s 3D Bioprinted Breast Implants Implant design 3D printed Breast Printed implant Implantation and Implant replacement using M&S* scaffold: vascularization by newly formed methodologies rhColl-MA based tissue formulation * M&S – Modeling & Simulation 27
Slide 28: Our Solutions For Advancing Medicine Without Animals
Our Solutions For Advancing Medicine Without Animals Mayo Clinic Devises First-Ever Skin-on-a Chip: Published in the Archives of Dermatological FDA “New Approach Research – the first fully humanized 3D Methodologies” (NAMS): bioprinted skin model using CollPlant’s Designed to improve drug safety rhC
Slide 29: Seasoned Management Team with Engineering, Pharmaceutical, Device and Life Sciences Experience
Seasoned Management Team with Engineering, Pharmaceutical, Device and Life Sciences Experience Yehiel Tal Eran Rotem Jasmine Seror, PhD CEO Deputy CEO & CFO VP Product Development Regentis Biomaterials Tefron, CFO (NYSE,TASE) Weizmann Institute of Science ProChon Biotech Healthcare Tech., CFO Kulick
Slide 30: Investment Summary
Investment Summary Proprietary, Plant-Based Targeting Large, High-Growth Broadly Applicable and Clinically rhCollagen Technology Platform Markets Validated Technology The only commercially scalable platform Advancing innovative regenerative medical A differentiated regenerative medicine platform cap
Slide 31: Thank you!
() CollPlant Thank you! Biotechnologies
CollPlant Biotechnologies — Investor Presentation (2026) on 6ix